© 2023 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
In honor Frederick G. Banting’s birth 125 years ago today, we present a review of developments in insulin for the year 2016.
From potential new insulin formulations to the first FDA-approved automated insulin delivery device, to fine-tuning insulin dose calculations, 2016 has seen many important developments in insulin.See the slide legends for links to the article summaries.
In honor Frederick G. Banting’s birth 125 years ago today, we present a review of developments in insulin for the year 2016.
Obese Patients with Type 2 Diabetes on Conventional Versus Intensive Insulin Therapy: Efficacy of Low-Calorie Dietary Intervention. Abstract link.****BeAM Value: an Indicator of the Need to Initiate and Intensify Prandial Therapy in Patients with Type 2 Diabetes Mellitus Receiving Basal Insulin. Abstract Link. See also: Targeting Insulin Doses in Type 2 Diabetes.
Major Adverse Cardiovascular Events with Basal Insulin Peglispro versus Comparator Insulins in Patients with Type 1 or Type 2 Diabetes: a Meta-Analysis. Abstract Link. See also: Cardiovascular Risks with Insulins. ****Comparing the Clinical Outcomes Between Insulin-treated and Non-insulin-treated Patients with Type 2 Diabetes Mellitus after Coronary Artery Bypass Surgery: a Systematic Review and Meta-Analysis. Abstract link.
FDA Approves First Automated Insulin Delivery Device for Type 1 Diabetes. Press release. ****Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes Abstract link.
FDA Approves a Dedicated Syringe to be Used with Humulin R U-500 Insulin. Abstract link. ****FDA Approves Basaglar, the First “Follow-on” Insulin Glargine Product to Treat Diabetes. Press release.
Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: an Endocrine Society Clinical Practice Guideline. Abstract link. See also: New Diabetes Guidelines: Insulin Pumps & CGM. ****Optimized Mealtime Insulin Dosing for Fat and Protein in Type 1 Diabetes: Application of a Model-Based Approach to Derive Insulin Doses for Open-Loop Diabetes Management. Abstract link. See also: Rethink Optimal Insulin Dose Calculations.
Insulin Prices Soar While Drugmakers’ Share Stays Flat. Abstract link. See also: Cost Analysis: Insulin & Other Antihyperglycemics. ****Bernie Sanders Requests Federal Investigation of Insulin Makers for Price Collusion. Abstract Link. ****
Formulation of Insulin for Oral Dosing. Abstract link. See also New Formulation to Deliver Insulin Orally. ****Determining Starting Basal Rates of Insulin Infusion for Insulin Pump Users: a Comparison between Methods. Abstract link. See also: Starting Insulin Rates in Pump Users.
Biosimilars and New Insulin Versions. Abstract Link. See also: New Insulin Versions on the Horizon.**** Construction of Insulin 18-mer Nanoassemblies Driven by Coordination to Iron(II) and Zinc(II) Ions at Distinct Sites. Abstract link. See also: One Step Closer to Designer Insulin.
Potential Diabetes Treatment Uses Light-Activated Gel to Release Insulin. Abstract link. ****Efficacy and Safety of Oral Insulin Compared to Subcutaneous Insulin: a Systematic Review and Meta-Analysis. Abstract link.